Eribulin Mesilate

Adenocarcinoma

Swiss Cancer InstitutePhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

27 Active assets in the Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II Mayo Clinic	Phase 4	BBB
Carboplatin Blueprint Medicines Corporation	Phase 4	BBB
Irinotecan University of Chicago	Phase 2	BBB
Icotinib Betta Pharmaceuticals Co., Ltd.	Phase 4	BB
Cyclophosphamide M.D. Anderson Cancer Center	Phase 3	BB

View all 50 →

Same molecule, other indications

Eribulin Mesilate is also rated in:

breast cancerDormant

B

Indicative ·

58 / 100

triple-negative breast carcinomaDormant

CCC

Indicative ·

52 / 100

Refractory or Recurrent Solid TumorsDormant

CCC

Indicative ·

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.